Alembic set to raise $150-200 million via stake sale

Alembic launched about 22 generic drugs in the US in the previous fiscal year, with a further 10 products planned for launch in the first half of the current financial year. It has a strong presence in the anti-diabetic, cardiology, nephrology, gynaecology, cough and cold and anti-infectives segments.

from Stocks-Markets-Economic Times https://ift.tt/3g53A7J